Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause
Journal of Pharmacy Technology · 2026-08 · 42 (4) · 201-207
DOI: 10.1177/87551225261436749 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy Technology, online erschienen am 19.04.2026. Verfasst von Lisa Miller. Beteiligte Einrichtung: Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To review the pharmacology, pharmacokinetics, efficacy, safety, and clinical role of elinzanetant for the treatment of vasomotor symptoms (VMS) associated with menopause. Data Sources: PubMed and Google Scholar were searched for English-language articles published through January 2026 using the terms elinzanetant, NT-814, OASIS, SWITCH, vasomotor symptoms, and menopause. Study Selection and Data Extraction: Phase 2 and phase 3 clinical trials evaluating elinzanetant in postmenopausal women with moderate to severe VMS were included. Data Synthesis: Elinzanetant is a dual neurokinin-1 (NK-1) and neurokinin-3 (NK-3) receptor antagonist targeting hypothalamic pathways involved in thermoregulation. Clinical trials demonstrated statistically significant reductions in VMS frequency and severity compared with placebo. Efficacy was observed as early as week 1 and sustained across treatment periods. Elinzanetant was generally well tolerated, including in long-term studies and in women receiving endocrine therapy for breast cancer.
Conclusion
Elinzanetant represents an additional nonhormonal treatment option for menopausal VMS. As a dual NK-1 and NK-3 receptor antagonist, it differs mechanistically from selective NK-3 antagonists and may offer an alternative for patients who are not candidates for hormone therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL, USA.
ORCID-Profile: Lisa Miller
Zitieren
APA
Miller, L. (2026). Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause. Journal of Pharmacy Technology, 42(4), 201-207. https://doi.org/10.1177/87551225261436749
Vancouver
Miller L. Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause. Journal of Pharmacy Technology. 2026;42(4):201-207. doi:10.1177/87551225261436749
BibTeX
@article{Miller2026,
author = {Miller, Lisa},
title = {Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause},
journal = {Journal of Pharmacy Technology},
year = {2026},
volume = {42},
number = {4},
pages = {201--207},
doi = {10.1177/87551225261436749}
}
EUVIMED